Encyclopedia entry

Selank

Evidence: Mixed evidence

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-06-04

Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.

AI-friendly summary · Selank

Selank is a synthetic 7-amino-acid peptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analog of Tuftsin extended by a Pro-Gly-Pro sequence to increase metabolic stability. It is registered in Russia for generalised anxiety and neurasthenia indications. Outside Russia, including in the UK and the broader EU, Selank has no marketing authorisation from any regulator.

Selank: a synthetic heptapeptide analog of the endogenous immunomodulator Tuftsin. Registered as a pharmaceutical in Russia. Not licensed by MHRA or EMA. Research use only in the UK.

Mechanism of action

How Selank works

Selank is structurally derived from Tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide with immunomodulatory activity, extended at the C-terminus by a Pro-Gly-Pro sequence to slow enzymatic degradation. The proposed mechanism in animal studies involves modulation of brain enkephalin levels and effects on serotonergic and GABAergic neurotransmission. The exact receptor target in humans is not established. The mechanism underlying the anxiolytic-like effects reported in Russian clinical studies has not been characterised to the standard required by EMA or FDA submissions.

Source: Institute of Molecular Genetics, Russian Academy of Sciences (Kozlovskaya et al.)

What the Russian clinical literature shows

Selank has roughly 40 to 50 peer-reviewed papers indexed on PubMed, the majority from the originating Russian research group. The compound holds Russian pharmaceutical registration as a nasal spray. The clinical evidence base by western regulatory standards is methodologically limited: small single-site trials, predominantly Russian-language publications, designs that pre-date current ICH-GCP standards.

· Russian-language clinical studies, primarily conducted at institutes under the Russian Academy of Sciences, reported anxiolytic-like effects in human participants with generalised anxiety and neurasthenia diagnoses.
· Animal studies reported effects on brain enkephalin and monoamine levels in rodent models.
· The compound achieved Russian pharmaceutical registration, which required submission of clinical dossiers to Russian regulatory authorities.
· The Russian clinical data exists in peer-reviewed form (some papers translated into or published in English), but trials were generally small, single-site, and used methodological designs that would not meet current FDA, EMA, or MHRA RCT standards.
· Russian pharmaceutical registration is not equivalent to, and does not confer, EU or UK marketing authorisation.
· Wide availability in Russian pharmacies is a consequence of domestic regulatory approval, not evidence of efficacy by western regulatory standards.

Sister compound: Semax (see Semax encyclopedia entry) is a separate Russian-developed peptide with a different mechanism and target indication, often paired with Selank in research discussions.

UK regulatory status

Selank sits outside the Misuse of Drugs Act 1971 and outside the Psychoactive Substances Act 2016. It holds no UK or EU marketing authorisation as a medicine. Russian pharmaceutical registration does not apply in either jurisdiction. UK retailers can sell it lawfully only by labelling it for "research use only" and avoiding any therapeutic claim.

· Not a controlled drug under the Misuse of Drugs Act 1971.
· Not scheduled under the Psychoactive Substances Act 2016.
· No MHRA marketing authorisation as a medicine in the UK.
· Not authorised by the EMA for use in any EU member state.
· Russian registration does not apply in the UK or EU regulatory jurisdictions.
· Sold legally as a research chemical by UK retailers when marketed without therapeutic claims.
· Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Risks and unknowns

What the literature does not yet show about Selank

Known concerns

Clinical evidence base is methodologically limited by western regulatory standards. Small single-site trials predominate.
Russian pharmaceutical registration does not equate to MHRA or EMA approval. Independent replication outside the originating institution is limited.
Purity of UK research-peptide supply varies between retailers. CoA gating and HPLC analysis differ.
Russian regulatory submission requirements at the time of registration differed from current EMA or MHRA standards.

Open questions in the literature

The precise receptor target and full mechanism in humans has not been characterised to western regulatory standards.
Long-term safety beyond Russian-trial duration is not characterised in EMA-equivalent evidence.
Whether the Russian clinical signal would replicate in a modern ICH-GCP randomised trial is unknown.
Interactions with western-licensed psychiatric medications have not been formally studied.

Regulatory note

Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK or EU marketing authorisation as a medicine. Russian registration does not apply in the UK. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.

Where to learn more

· PubMed search: Selank returns Russian-authored and translated papers covering animal pharmacology and the clinical programme.
· PubMed: Kozlovskaya et al. for the originating Russian research-group publications.
· Sister compound: Semax encyclopedia entry.
· UK retailer purity comparison: research peptides UK retailers.

Frequently asked questions

Is Selank legal in the UK?

Selank is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is sold legally by UK research peptide retailers under "research use only, not for human or animal consumption" framing. It holds no UK marketing authorisation as a medicine.

What does the human evidence show for Selank?

Russian-language clinical studies, primarily conducted at institutes under the Russian Academy of Sciences, reported anxiolytic-like effects in human participants. The trials were generally small, single-site, and used methodological designs that would not meet current FDA, EMA, or MHRA randomised controlled trial standards. No western regulatory submission has been made.

What is the regulatory status of Selank in the UK?

Selank has no MHRA marketing authorisation as a medicine in the UK and no EMA authorisation in the EU. Russian pharmaceutical registration does not apply in either jurisdiction. Sold as a research chemical when marketed without health claims, but becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims.

What forms is Selank available in?

In Russia, Selank is registered as a nasal-spray pharmaceutical (the brand Selank N-Pharm). UK research peptide retailers list it most commonly as lyophilised powder in 5mg or 10mg vials for reconstitution. Some retailers offer pre-mixed nasal sprays. PeptideClear publishes no dosing or human-use instructions.

Where can I learn more about Selank?

A PubMed search for "Selank" returns a mix of Russian-authored and translated papers covering the animal pharmacology and the Russian clinical programme. The Institute of Molecular Genetics (Russian Academy of Sciences) is the primary research source. The "Where to learn more" section links to the available primary sources.

Where to buy Selank in the UK

Compare UK research-peptide retailers stocking Selank, with current prices and CoA status. Research use only, not for human or animal consumption.

Compare Selank prices

Clinical evidence record

Read the clinical evidence record for Selank

Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.

Popular on PeptideClear

Research peptides

BPC-157 (UK)

Collagen

Best UK collagen brands 2026

GLP-1

UK GLP-1 clinics compared

Methodology

CoA Trust Index

Shop

BPC-157 UK prices

Ready to buy

Buy Selank in the UK

UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.

Buy Selank in the UK CoA Trust Index